Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle

Authorised

- Penethamate hydriodide
- Framycetin sulfate
- Benethamine penicillin

Product identification

Medicine name:
Ubrostar Red 100 mg / 280 mg / 100 mg Intramammary Suspension for cattle
Ubrostar Dry Cow 100 mg / 280 mg / 100 mg intramammaire suspensie voor runderen

Active substance:
Penethamate hydriodide

Framycetin sulfate

Benethamine penicillin

Target species:
Cattle

Route of administration:
Intramammary use

Product details

Active substance and strength:

Penethamate hydriodide
100.00 milligram(s) / 1.00 Syringe

Framycetin sulfate
100.00 milligram(s) / 1.00 Syringe

Benethamine penicillin
280.00 milligram(s) / 1.00 Syringe

Pharmaceutical form:

Intramammary suspension

Withdrawal period by route of administration:

Intramammary use:

- **Cattle**
  - Meat and offal. 10 day
  - Milk. 37 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ51RC25

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Netherlands

Package description:

Cardboard box or plastic container containing 20 single useintramammary syringes and 20 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.

Cardboard box or plastic container containing 60 single useintramammary syringes and 60 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.
Cardboard box or plastic container containing 120 single useintramammary syringes and 120 teat wipes (containing isopropanol 70%).Each 4.5 g syringe (cylinder with piston and cap, all made of low densitypolyethylene) contains 5 ml intramammary suspension.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
8/11/1992

Manufacturing sites for batch release:
Lohmann Pharma Herstellung GmbH
Haupt Pharma Latina S.r.l.

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 108011

Date of authorisation status change:
26/01/2022

Reference member state:
Ireland

Procedure number:
IE/V/0271/001

Concerned member states:
Austria Belgium Bulgaria Cyprus Czechia Estonia France Germany Greece Hungary Latvia Lithuania Netherlands Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics

Source URL: *https://medicines.health.europa.eu/veterinary/600000052232*